WHO Drug Information Vol. 23, No. 1, 2009 - World Health ...

More documents

Recommendations

Info

WHO Drug Information Vol 23, No. 1, 2009Recent Publications, Information and Eventssources, as well as indicative prices ofmedicines in formulations suitable forchildren.This publication contributes to the effort toincrease access to appropriate medicinesby identifying sources and prices forselected products indicated in the treatmentof diseases in children. The list ofproducts selected is based on the ‘ModelList of Essential Medicines for Children’ athttp://www.who.int/childmedicines/publications/EMLc%20(2).pdfReference: http://www.unicef.org/supply/index_47129.htmlTwo international summercourses in the NetherlandsThe Division of Pharmacoepidemiologyand Pharmacotherapy at Utrecht University,the Netherlands, is offering twochallenging international summer coursesin Pharmacoepidemiology and DrugSafety and Pharmaceutical Policy Analysis(in collaboration with WHO). Bothcourses will cover key issues in each fieldand focus on the most important researchmethods used. All course teachers haveextensive expertise in their field. Inaddition, there is a cultural and socialprogramme arranged to make sure thatparticipants experience the best ofUtrecht.M8 Pharmacoepidemiology and DrugSafety (29 June – 3 July 2009)With the prospect that innovative drugtherapies will be introduced in the comingyears, society demands new approachesand concepts for comparative risk/benefitevaluation. These evaluations are carriedout once therapies have been usedwidely in daily practice. Assessment ofsafety and risk management of differentdrug therapies is done in the frameworkof observational epidemiological studies(proof of safety, proof of effectiveness).This is the logical next step after randomizedclinical trials, which are designedto provide evidence of efficacy.The course will cover key issues inpharmacoepidemiologic and drug safetyresearch. Special topics include databases and molecular pharmacoepidemiology.All course teachers have extendedexpertise in the design and conduct ofpharmacoepidemiologic studies.The intensive programme covers thefollowing topics:• Study design and methods.• Confounding and other biases.• Methods in drug safety research.• Drug safety and risk management.• Overview of pharmacoepidemiologicaldatabases.• Molecular pharmacoepidemiology.• Drug utilization research.• Synthesis, case studies and publichealth.M7 International Pharmaceutical PolicyAnalysis (6–10 July 2009)Medicines are among the most regulatedproducts in society. From the earliest preclinicalstages onward, policy makerswant to foster the development of safe,effective and affordable medicines forpatients in need of pharmacotherapy.When a drug reaches the market, it is thebeginning of a process of complexinteractions between patients, prescribers,insurers, pharmaceutical companiesand governments. Furthermore, from aglobal perspective, the reality is that twobillion people do not have access toessential medicines. The inequity inaccess to medicines is still a definingcharacteristic of the global pharmaceuticalmarket place.This course will cover these issues from ascientific, regulatory, public health and47
Recent Publications, Information and EventsWHO Drug Information Vol 23, No. 1, 2009international policy perspective. As acollaborator on this course, WHO willprovide faculty for several of the sessions.An intensive programme covers thefollowing topics:• New medicines policy — methods forevaluating policy.• Methods in pharmaceutical policyanalysis.• Pharmacoepidemiology contribution topharmaceutical policy analysis.• Drug usage, adherence to therapy andpatient needs.• Regulatory issues and challenges.• Access, affordability and reimbursementsystems.• Ethics and equity.• Current challenges in drug innovation.• Synthesis, case studies and publichealth.Reference: www.utrechtsummerschool.nl/Global Politics ofPharmaceutical MonopolyThis new book explains why the twinchallenges of high medicines cost and theabsence of appropriate or effectivetreatments for many of the diseasesaffecting patients are in fact twosides of the same coin. It analyses thelatest mechanisms and policy changesthat may help repair the broken system ofmedical innovation and access to medicinestoday.In particular, the book highlights recentalternative mechanisms to encouragemedical research and development in away that also ensures access to thedeveloped product by separating the costof research and development from theprice of diagnostics, medicines, andvaccines.The objective of the book is to spur effortstowards a patent pool, to speed upaccess to newer medicines, and boostinitiatives that make use of alternativefinancing mechanisms in order to developnew, more appropriate treatments thatrespond to medical needs.An open access version of The Global Politicsof Pharmaceutical Monopoly Power is freelyavailable on the MSF Access Campaignwebsite: http://www.msfaccess.org48
Page 2 and 3: WHO Drug Information Vol 23, No. 1,
Page 50 and 51: WHO Drug Information, Vol. 23, No.
Page 84: WHO Drug Information, Vol. 23, No.

WHO Drug Information Vol. 23, No. 1, 2009 - World Health ...

Create successful ePaper yourself

Delete template?

Save as template?